Crohn's disease

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTYX

Retrieved on:

Wednesday, April 3, 2024

Titan, Psoriasis, Plaintiff, Class, IPO, Crohn's disease, Advertising, Court

WHAT TO DO NEXT: To join the Ventyx class action, go to https://rosenlegal.com/submit-form/?case_id=22943 or call Phillip Kim, Esq.

Key Points:

WHAT TO DO NEXT: To join the Ventyx class action, go to https://rosenlegal.com/submit-form/?case_id=22943 or call Phillip Kim, Esq.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Breakthroughs in Kexing Biopharm's Overseas Efforts: Qualification of Two Licensed Products for GMP Audits in Egypt

Retrieved on:

Tuesday, April 2, 2024

Ulcerative colitis, Psoriasis, Rheumatoid arthritis, Growth, Ankylosing spondylitis, Drug, EDA, Ageing, Kingdom Holding Company, Crohn's disease, Lung cancer, GMP, Bevacizumab, Infliximab, Pharmaceutical industry

In 2022, Kexing Biopharm secured agreements with 24 overseas market customers and commenced the submission of local drug access registration documents.

Key Points:

In 2022, Kexing Biopharm secured agreements with 24 overseas market customers and commenced the submission of local drug access registration documents.
The product underwent GMP audits in Egypt, Brazil, and Indonesia respectively in September 2023, February 2024, and March 2024.
In 2022, Kexing Biopharm swiftly reached agreements with 23 overseas market customers, initiating the submission of drug access registration documents.
By establishing local subsidiaries, Kexing Biopharm strives to accelerate product registration processes and enhance competitiveness in overseas markets.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTYX

Retrieved on:

Tuesday, April 2, 2024

Titan, Psoriasis, Plaintiff, Class, IPO, Crohn's disease, Advertising, Court

WHAT TO DO NEXT: To join the Ventyx class action, go to https://rosenlegal.com/submit-form/?case_id=22943 or call Phillip Kim, Esq.

Key Points:

WHAT TO DO NEXT: To join the Ventyx class action, go to https://rosenlegal.com/submit-form/?case_id=22943 or call Phillip Kim, Esq.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTYX

Retrieved on:

Wednesday, March 27, 2024

Titan, Psoriasis, Plaintiff, Class, IPO, Crohn's disease, Advertising, Court

WHAT TO DO NEXT: To join the Ventyx class action, go to https://rosenlegal.com/submit-form/?case_id=22943 or call Phillip Kim, Esq.

Key Points:

WHAT TO DO NEXT: To join the Ventyx class action, go to https://rosenlegal.com/submit-form/?case_id=22943 or call Phillip Kim, Esq.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - VTYX

Retrieved on:

Tuesday, March 26, 2024

Titan, Psoriasis, Plaintiff, Class, IPO, Crohn's disease, Advertising, Court

WHAT TO DO NEXT: To join the Ventyx class action, go to https://rosenlegal.com/submit-form/?case_id=22943 or call Phillip Kim, Esq.

Key Points:

WHAT TO DO NEXT: To join the Ventyx class action, go to https://rosenlegal.com/submit-form/?case_id=22943 or call Phillip Kim, Esq.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, and Anavex and Encourages Investors to Contact the Firm

Retrieved on:

Tuesday, April 9, 2024

Psoriasis, Form, Patient, Defendant, News, IPO, Crohn's disease, Security (finance), Inflammation, Rett syndrome, Prospectus, Complaint, P.C, Clinical trial, MCI, Radar, File, Register, Pharmaceutical industry

The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Key Points:

The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.
For more information on the Anavex class action go to: https://bespc.com/cases/AVXL

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hut 8, Ventyx, and Anavex and Encourages Investors to Contact the Firm

Retrieved on:

Friday, April 5, 2024

In November 2023, Hut 8 formed following the merger of Hut 8 Mining Corp. (“Legacy Hut”) and U.S. Data Mining Group, Inc. d/b/a US Bitcoin Corp. (“USBTC”) (the “Merger”).

Key Points:

In November 2023, Hut 8 formed following the merger of Hut 8 Mining Corp. (“Legacy Hut”) and U.S. Data Mining Group, Inc. d/b/a US Bitcoin Corp. (“USBTC”) (the “Merger”).
USBTC held a 50% interest in a joint venture bitcoin mining facility, located in King Mountain, Texas (the “King Mountain JV”), which was acquired in the Merger.
In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
For more information on the Anavex class action go to: https://bespc.com/cases/AVXL

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Children’s Place, and Ventyx and Encourages Investors to Contact the Firm

Retrieved on:

Monday, April 1, 2024

Psoriasis, Form, Defendant, News, IPO, Crohn's disease, Security (finance), Inflammation, Prospectus, Complaint, P.C, File, Register

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.

Key Points:

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.
Therein, the Company revealed that it now expected fourth quarter net sales between $454 million and $456 million, falling short of previously issued guidance.
In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
As of the time the Complaint was filed, the price of Ventyx common stock continues to trade below the $16.00 per share Offering price, damaging investors.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Children’s Place, and Ventyx and Encourages Investors to Contact the Firm

Retrieved on:

Thursday, March 28, 2024

Psoriasis, Form, Defendant, News, IPO, Crohn's disease, Security (finance), Inflammation, Plaque, Prospectus, Complaint, P.C, File, Register

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.

Key Points:

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.
Therein, the Company revealed that it now expected fourth quarter net sales between $454 million and $456 million, falling short of previously issued guidance.
In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
As of the time the Complaint was filed, the price of Ventyx common stock continues to trade below the $16.00 per share Offering price, damaging investors.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Children’s Place, and Ventyx and Encourages Investors to Contact the Firm

Retrieved on:

Sunday, March 24, 2024

Psoriasis, Form, Defendant, News, IPO, Crohn's disease, Security (finance), Inflammation, Prospectus, P.C, File, Register

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.

Key Points:

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.
Therein, the Company revealed that it now expected fourth quarter net sales between $454 million and $456 million, falling short of previously issued guidance.
In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
As of the time this Complaint was filed, the price of Ventyx common stock continues to trade below the $16.00 per share Offering price, damaging investors.